“At Hansa Biopharma we envision a world where patients with rare immunologic diseases can lead long and healthy lives.
We are dedicated to attaining market approval for the ﬁrst treatment that potentially may enable kidney transplantation in highly sensitized patients.”
Søren Tulstrup President and CEO of Hansa Biopharma
A world where all patients with rare immunologic diseases can lead long and healthy lives.
We leverage our unique enzyme technology platform to develop innovative, lifesaving and life altering immunomodulating therapies, bring these to the patients with rare diseases who need them, and generate value to society at large.
Our goal is to create value for patients, healthcare providers, societies and our shareholders. We are striving to develop therapies for patients with an unmet medical need and bringing our drugs all the way from the laboratory to the patients.
Hansa Biopharma has applied for marketing authorization of imlifidase for enabling kidney transplantation in highly sensitized patients in the EU. The Marketing Authorization Application is currently under review by the European Medicines Agency. We are in dialogue with the U.S. Food and Drug Administration to pursue a regulatory path forward.
We have initiated three Phase 2 clinical studies in autoimmune indications; Guillain-Barré Syndrome (GBS), Goodpasture’s syndrome (anti-GBM antibody disease) and acute Antibody-Mediated Rejection (AMR) in kidney transplantation.
We have selected a lead candidate in the NiceR program and are exploring the opportunities for repeat dosing in a range of conditions including relapsing autoimmune diseases, chronic transplant rejection, pre-treatment in oncology and in combination with gene therapy.